Spiriva
Sponsors
Boehringer Ingelheim, Shanghai Pulmonary Hospital, Shanghai, China, AstraZeneca, Fundacio Privada Mon Clinic Barcelona
Conditions
AsthmaBronchiectasisCOPDChronic Obstructive Pulmonary DiseaseHealthyHealthy VolunteersPulmonary Disease, Chronic Obstructive
Phase 1
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
CompletedNCT02263976
Start: 2003-08-31Updated: 2014-10-15
PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium
CompletedNCT03097380
Start: 2017-04-26End: 2017-12-30Updated: 2021-08-30
Phase 4
SPIRIVA in Ususal Care
CompletedNCT00274079
Start: 2002-10-31End: 2003-10-31Target: 395Updated: 2013-11-01
Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis
NCT02546297
Start: 2017-09-15End: 2021-03-01Target: 90Updated: 2019-08-01
ANTES B+ Clinical Trial
TerminatedNCT06282861
Start: 2024-02-29End: 2025-01-23Updated: 2025-08-14
Unknown Phase
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
CompletedNCT02172547
Start: 2006-04-30Updated: 2014-06-24
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
CompletedNCT02489981
Start: 2015-06-01End: 2017-09-28Updated: 2019-02-11